



GoodRx Now Offers Novo Nordisk's Cash Price for the Launch of the Wegovy® Pill

January 5, 2026

Consumers can soon go to GoodRx for Weight Loss to determine eligibility and obtain a prescription for the first and only oral GLP-1 formulation

SANTA MONICA, Calif.--(BUSINESS WIRE)--Jan. 5, 2026-- GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved [Wegovy® pill](#) (oral semaglutide) is now available at a cash price of \$149 per month at more than 70,000 pharmacies nationwide via GoodRx. For consumers looking to easily evaluate their options for both treatment and access to the medication, they will soon be able to connect with a licensed healthcare provider through [GoodRx for Weight Loss](#) to determine eligibility and obtain a prescription when appropriate. The arrival of the Wegovy pill on GoodRx represents a significant step forward in making GLP-1 treatments more affordable and accessible for people looking to begin or advance their weight-loss journey.

"We're excited to help consumers access one of the most anticipated weight-loss treatments on the market," said Wendy Barnes, President and CEO of GoodRx. "As new oral GLP-1 options emerge, GoodRx is uniquely positioned to support patients as they navigate their treatment choices. By combining transparent cash pricing with streamlined access to care and broad pharmacy availability, we're helping usher in a simpler, more consumer-friendly chapter in weight management treatment."

Lowest Discounted Cash Prices for First Oral GLP-1

The [Wegovy pill](#) is now available on GoodRx to eligible self-pay patients at a cash price of \$149 per month for the two lowest doses (1.5mg and 4mg).^{*} With industry-leading cash prices across all FDA-approved doses and availability at more than 70,000 retail pharmacies nationwide, GoodRx ensures that consumers can access the Wegovy pill quickly, reliably, and with meaningful savings.

A Streamlined Path Through GoodRx for Weight Loss

Consumers who need help determining whether the Wegovy pill is appropriate for them will soon be able to turn to [GoodRx for Weight Loss](#), the company's telemedicine subscription that is designed specifically for people seeking weight management support. Through this offering, users can meet with licensed healthcare providers, discuss treatment options, complete eligibility assessments, and—when clinically appropriate—receive a prescription for the Wegovy pill or other FDA-approved GLP-1 treatments. GoodRx for Weight Loss also provides ongoing support, clear pricing, and flexible fulfillment options.

Supporting Pharma Manufacturers With Scalable Cash-Pay Solutions

The introduction of these new lowest discounted cash prices for the Wegovy pill demonstrates how GoodRx can help pharmaceutical manufacturers bring new cash-pay programs to market quickly and at scale. With millions of consumers turning to GoodRx each month to evaluate medication affordability options, manufacturers can immediately surface clear, competitive pricing to patients on day one of availability. GoodRx's extensive pharmacy network, trusted brand, and established consumer engagement channels enable partners to rapidly scale awareness, streamline access, and accelerate adoption.

**The Wegovy pill is now available to eligible self-pay patients at a cash price of \$149 per month for the two lowest doses (1.5mg and 4mg) through April 15, 2026, after which a \$199 per month cash price will apply to the 4mg. The cash price for the Wegovy pill 9mg and 25mg is \$299 per month.*

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over \$85 billion on the cost of their medications.

GoodRx periodically posts information that may be important to investors on its investor relations website at <https://investors.goodrx.com>. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of Wegovy pill and related pricing; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and our other filings with the SEC. Any such forward-looking statements are based on current expectations,

projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260105738223/en/): <https://www.businesswire.com/news/home/20260105738223/en/>

Media Contact

press@goodrx.com

Source: GoodRx